Table 1 Differences in treatment parameters between treated and untreated eyes at the three time points and annual changes in AL during the observation and treatment periods.

From: Evaluation of axial length to identify the effects of monocular 0.125% atropine treatment for pediatric anisometropia

Parameter

Treated eye (N = 20)

Untreated eye (N = 20)

p value*

SEQ at first visit (D)

− 0.55 ± 1.11

0.67 ± 1.14

 < 0.001

AL at first visit (mm)

23.63 ± 1.21

23.16 ± 1.04

 < 0.001

SEQ before treatment (D)

–1.25 ± 0.94

0.15 ± 1.29

 < 0.001

AL before treatment (mm)

23.91 ± 1.02

23.35 ± 0.92

 < 0.001

SEQ after treatment (D)

− 1.39 ± 1.16

–0.67 ± 1.29

0.004

AL after treatment (mm)

23.97 ± 1.06

23.70 ± 1.01

0.005

Annual changes in AL (mm)

Observation period (mean = 10.7 months, median = 4.7 months, N = 16)

0.40 ± 0.26

0.21 ± 0.140

0.008

Treatment period (mean = 13.7 months, median = 11.6 months)

− 0.03 ± 0.21

0.32 ± 0.24

 < 0.001

  1. *p < 0.05, paired t test.
  2. Continuous data are expressed as mean ± standard deviation.
  3. SEQ, spherical equivalent refractive error; AL, axial length; N, number of eyes.
Back to article page